Recombinant CD40-ligand

DB15015Investigational

Recombinant CD40-ligand is under investigation in clinical trial NCT00053391 (Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma).

Mechanism: Pharmacologically active on Tumor necrosis factor receptor superfamily member 5
Curator reviewed
Also known as: CD40 ligand
Code names: AMG-950

Resolves to

Compound

UNIIT169OM1T8L

Targets

P25942CD40

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

6Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Recombinant CD40-ligand, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account